Boston Common Asset Management LLC Reduces Stake in Gilead Sciences, Inc. $GILD

Boston Common Asset Management LLC reduced its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 8.6% in the first quarter, Holdings Channel reports. The fund owned 77,243 shares of the biopharmaceutical company’s stock after selling 7,238 shares during the quarter. Boston Common Asset Management LLC’s holdings in Gilead Sciences were worth $10,765,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors also recently modified their holdings of the company. Vanguard Group Inc. lifted its stake in Gilead Sciences by 1.8% in the fourth quarter. Vanguard Group Inc. now owns 121,097,336 shares of the biopharmaceutical company’s stock valued at $14,863,487,000 after purchasing an additional 2,113,692 shares during the last quarter. State Street Corp grew its holdings in Gilead Sciences by 1.9% during the fourth quarter. State Street Corp now owns 60,240,518 shares of the biopharmaceutical company’s stock valued at $7,393,921,000 after purchasing an additional 1,151,213 shares during the period. Price T Rowe Associates Inc. MD increased its position in Gilead Sciences by 4.5% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 27,698,660 shares of the biopharmaceutical company’s stock worth $3,399,734,000 after buying an additional 1,195,269 shares during the last quarter. Bank of America Corp DE increased its position in Gilead Sciences by 15.2% in the fourth quarter. Bank of America Corp DE now owns 23,121,620 shares of the biopharmaceutical company’s stock worth $2,837,948,000 after buying an additional 3,046,688 shares during the last quarter. Finally, Norges Bank bought a new stake in shares of Gilead Sciences in the fourth quarter valued at $2,617,152,000. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Gilead Sciences Stock Performance

NASDAQ:GILD opened at $134.28 on Monday. The company has a market cap of $166.72 billion, a P/E ratio of 18.29 and a beta of 0.32. The stock’s fifty day moving average price is $129.73 and its two-hundred day moving average price is $135.30. Gilead Sciences, Inc. has a 1 year low of $107.75 and a 1 year high of $157.29. The company has a debt-to-equity ratio of 0.89, a current ratio of 1.97 and a quick ratio of 1.77.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Thursday, May 7th. The biopharmaceutical company reported $2.03 EPS for the quarter, topping analysts’ consensus estimates of $1.91 by $0.12. The firm had revenue of $6.96 billion during the quarter, compared to analyst estimates of $6.91 billion. Gilead Sciences had a return on equity of 48.19% and a net margin of 30.99%.The business’s revenue for the quarter was up 4.4% on a year-over-year basis. During the same period last year, the company earned $1.81 earnings per share. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. As a group, analysts expect that Gilead Sciences, Inc. will post -0.77 EPS for the current year.

Gilead Sciences Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Monday, June 29th. Shareholders of record on Monday, June 15th were paid a $0.82 dividend. The ex-dividend date was Monday, June 15th. This represents a $3.28 annualized dividend and a yield of 2.4%. Gilead Sciences’s dividend payout ratio (DPR) is currently 44.69%.

Analyst Upgrades and Downgrades

GILD has been the topic of a number of recent research reports. Leerink Partners dropped their price target on Gilead Sciences from $148.00 to $146.00 in a research report on Friday, May 8th. Citigroup lifted their price objective on Gilead Sciences from $156.00 to $165.00 and gave the stock a “buy” rating in a report on Monday, April 13th. Weiss Ratings cut Gilead Sciences from a “buy (b)” rating to a “buy (b-)” rating in a research note on Thursday, May 28th. Morgan Stanley dropped their price objective on shares of Gilead Sciences from $168.00 to $166.00 and set an “overweight” rating on the stock in a report on Wednesday, July 8th. Finally, HSBC upgraded shares of Gilead Sciences from a “hold” rating to a “buy” rating and increased their target price for the stock from $133.00 to $155.00 in a research report on Monday, July 6th. Twenty-six research analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $159.04.

Insiders Place Their Bets

In other news, CFO Andrew D. Dickinson sold 3,000 shares of the stock in a transaction dated Monday, June 15th. The shares were sold at an average price of $125.40, for a total value of $376,200.00. Following the sale, the chief financial officer directly owned 171,646 shares of the company’s stock, valued at approximately $21,524,408.40. This represents a 1.72% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Johanna Mercier sold 28,000 shares of the firm’s stock in a transaction that occurred on Friday, May 15th. The shares were sold at an average price of $131.29, for a total transaction of $3,676,120.00. Following the completion of the transaction, the insider owned 125,779 shares of the company’s stock, valued at $16,513,524.91. This trade represents a 18.21% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 77,000 shares of company stock worth $9,978,740 in the last quarter. 0.30% of the stock is owned by company insiders.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.